Cargando…
Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism
The intestinal capillary pathway is the most common way to absorb oral drugs, but for drugs with poor solubility and permeability and high first-pass metabolism, this pathway is very inefficient. Although intestinal lymphatic transport of lipophilic drugs or prodrugs is a promising strategy to impro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330727/ https://www.ncbi.nlm.nih.gov/pubmed/34338567 http://dx.doi.org/10.1080/10717544.2021.1960928 |
_version_ | 1783732779557584896 |
---|---|
author | Wang, Xinran Zhang, Cai Han, Ning Luo, Juyuan Zhang, Shuofeng Wang, Chunguo Jia, Zhanhong Du, Shouying |
author_facet | Wang, Xinran Zhang, Cai Han, Ning Luo, Juyuan Zhang, Shuofeng Wang, Chunguo Jia, Zhanhong Du, Shouying |
author_sort | Wang, Xinran |
collection | PubMed |
description | The intestinal capillary pathway is the most common way to absorb oral drugs, but for drugs with poor solubility and permeability and high first-pass metabolism, this pathway is very inefficient. Although intestinal lymphatic transport of lipophilic drugs or prodrugs is a promising strategy to improve the oral delivery efficiency of these drugs. The prodrug strategy for modifying compounds with Log P > 5 to promote intestinal lymphatic transport is a common approach. However, transport of poor liposoluble compounds (Log P < 0) through intestinal lymph has not been reported. Herein, triglyceride-mimetic prodrugs of scutellarin were designed and synthesized to promote intestinal lymphatic transport and increase oral bioavailability. Lymphatic transport and pharmacokinetic experiments showed that two prodrugs did promote intestinal lymphatic transport of scutellarin and the relative oral bioavailability was 2.24- and 2.45-fold of scutellarin, respectively. In summary, triglyceride-mimetic prodrugs strategy was used for the first time to study intestinal lymphatic transport of scutellarin with Log P < 0, which could further broaden the application range of drugs to improve oral bioavailability with the assistance of intestinal lymphatic transport. |
format | Online Article Text |
id | pubmed-8330727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-83307272021-08-09 Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism Wang, Xinran Zhang, Cai Han, Ning Luo, Juyuan Zhang, Shuofeng Wang, Chunguo Jia, Zhanhong Du, Shouying Drug Deliv Research Article The intestinal capillary pathway is the most common way to absorb oral drugs, but for drugs with poor solubility and permeability and high first-pass metabolism, this pathway is very inefficient. Although intestinal lymphatic transport of lipophilic drugs or prodrugs is a promising strategy to improve the oral delivery efficiency of these drugs. The prodrug strategy for modifying compounds with Log P > 5 to promote intestinal lymphatic transport is a common approach. However, transport of poor liposoluble compounds (Log P < 0) through intestinal lymph has not been reported. Herein, triglyceride-mimetic prodrugs of scutellarin were designed and synthesized to promote intestinal lymphatic transport and increase oral bioavailability. Lymphatic transport and pharmacokinetic experiments showed that two prodrugs did promote intestinal lymphatic transport of scutellarin and the relative oral bioavailability was 2.24- and 2.45-fold of scutellarin, respectively. In summary, triglyceride-mimetic prodrugs strategy was used for the first time to study intestinal lymphatic transport of scutellarin with Log P < 0, which could further broaden the application range of drugs to improve oral bioavailability with the assistance of intestinal lymphatic transport. Taylor & Francis 2021-08-02 /pmc/articles/PMC8330727/ /pubmed/34338567 http://dx.doi.org/10.1080/10717544.2021.1960928 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wang, Xinran Zhang, Cai Han, Ning Luo, Juyuan Zhang, Shuofeng Wang, Chunguo Jia, Zhanhong Du, Shouying Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism |
title | Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism |
title_full | Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism |
title_fullStr | Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism |
title_full_unstemmed | Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism |
title_short | Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism |
title_sort | triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330727/ https://www.ncbi.nlm.nih.gov/pubmed/34338567 http://dx.doi.org/10.1080/10717544.2021.1960928 |
work_keys_str_mv | AT wangxinran triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism AT zhangcai triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism AT hanning triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism AT luojuyuan triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism AT zhangshuofeng triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism AT wangchunguo triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism AT jiazhanhong triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism AT dushouying triglyceridemimeticprodrugsofscutellarinenhanceoralbioavailabilitybypromotingintestinallymphatictransportandavoidingfirstpassmetabolism |